Integrative genomic pan-cancer analysis reveals the prognostic significance of DEFB1 in tumors
This study highlights DEFB1's potential as a prognostic biomarker and its influence on the tumor immune microenvironment across different cancers. These findings suggest DEFB1 could be a target for future cancer therapies, although further studies are needed to validate these results.
Authors
- Ran Ding (ORCID: https://orcid.org/0000-0003-3564-1142)
- Lu Cao
- Hong‐Yu Yang (ORCID: https://orcid.org/0000-0003-2141-5814)
- Wang Li (ORCID: https://orcid.org/0000-0002-7298-5836)
- Yang Yang (ORCID: https://orcid.org/0000-0002-8737-590X)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Wangjing Hospital of China Academy of Chinese Medical Sciences (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1007/s12672-025-02340-6
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- National Natural Science Foundation of China